In continuation to Press Release dated July 4, 2023, and intimation dated December 1, 2023, Strides Pharma Science has informed that Stelis Biopharma, an associate company of Strides, has provided the following update about the transaction with Syngene to transfer Stelis’ Unit 3 multi-modal facility in Bengaluru: As informed vide the December 1, 2023, announcement, gross consideration for the transaction was INR 617 crores. Post certain adjustments, the net consideration receivable was INR 563.2 crores. On December 1, 2023, Stelis received INR 395 crores. Post completion of certain post-closing actions and final adjustments, Stelis has further received INR 158.2 crores on December 22, 2023. Syngene is withholding INR 10 crores, which shall be released post fulfilment of few additional conditions by Stelis.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: